BridgeMD
The Surf trial
EU CTIS ID: 2025-523898-42-00
What this study is testing
To determine the optimal dose and timing of intravenous ICG to achieve sufficient tumor-to background contrast in solid tumors and to evaluate whether ICG fluorescence imaging can accurately identify tumor margins during surgery.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years
- Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)
- Candidate for surgical resection with curative intent
- Ability to provide written informed consent
- Adequate organ function to undergo surgery and ICG administration
You likely can't join if
- Known allergy to Indocyanine Green (ICG), iodine, or shellfish
- Pregnant or breastfeeding
- Significant renal impairment (eGFR <50 mL/min/1.73 m²)
- Hyperthyroidism or other active thyroid disease
- Any condition deemed by the investigator to place the patient at undue risk or interfere with study procedures
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.